|
**Overview**: Autoimmune Bullous Dermatoses Dilution Panel**Introduction**: The Autoimmune Bullous Dermatoses Dilution Panel is a diagnostic tool designed to quantify bullous dermatoses antibodies using serum samples. In India, pemphigus and pemphigoid require titer monitoring for disease activity (anti-desmoglein titers correlate with severity, BP180/230 in bullous pemphigoid). Prevalence of autoimmune blistering diseases ~1-5 per 100,000, with pemphigus more common. Symptoms include blisters, erosions, oral lesions. High morbidity from underdiagnosis in rural areas, delayed therapy escalation leading to sepsis. Per immunology practices aligned with ICMR guidelines, the test employs immunoassay dilutions for titer quantification over 1-2 days with high specificity, valuable for monitoring response. This diagnostic falls under autoimmune skin screening and targets patients with positive bullous antibodies, addressing accurate titer assessment to guide steroids/rituximab. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise disease monitoring. Its serum-based approach ensures reliable detection.**Other Names**: Bullous Dil Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Dilution for titer monitoring; in India, used in dermatology clinics.**Purpose**: The test quantifies 4 parameters including anti-desmoglein titers to guide bullous disease monitoring, assess activity, inform therapy adjustments.**Test Parameters**: 1. Anti-Desmoglein 1 Titer, 2. Anti-Desmoglein 3 Titer, 3. Anti-BP180 Titer, 4. Anti-BP230 Titer.**Pretest Condition**: No fasting required; patients should report ongoing blisters or known bullous disease.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on blister status, treatment, prior titers, or family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of uncontrolled disease including infection, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret titers within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High titers indicate active disease, necessitating treatment escalation. Low titers may suggest remission.**Specialist Consultation**: Dermatologists should be consulted for management.**Additional Supporting Tests**: Biopsy, DIF for confirmation.**Test Limitations**: Titers may not always correlate with activity; comprehensive approach required.**References**: Indian Journal of Dermatology 2024, Bullous Disease Studies India 2023. |
